Introduction
In the rapidly evolving landscape of in vitro diagnostics (IVD), the quality of raw materials fundamentally determines the accuracy and reliability of diagnostic tests. Sekbio has emerged as a formidable player in this domain, establishing itself as a trusted IVD antibody manufacturer since its founding in 2020 . Headquartered in Shenzhen's Guangming District, this ISO 13485-certified company has quickly built a reputation for delivering high-performance immunoreagents to diagnostic manufacturers across more than 30 countries . By combining advanced protein expression platforms, AI-assisted development, and a customer-centric approach, Sekbio is actively shaping the future of diagnostic testing worldwide.
The Core of Sekbio's Expertise: IVD Antibody Raw Materials
At the heart of Sekbio's offerings lies an extensive portfolio of IVD antibody raw materials designed to meet the rigorous demands of modern diagnostic platforms. The company specializes in monoclonal antibodies, polyclonal antibodies, recombinant proteins, and pre-screened antibody pairs, all optimized for platforms including POCT, ELISA, CLIA, and FIA . Each product undergoes stringent quality control to ensure batch-to-batch consistency—a critical requirement for diagnostic manufacturers scaling from development to commercial production .
Sekbio's commitment to quality is demonstrated through its validation data: antibodies achieve batch-to-batch CV <10% with diagnostic-grade purity, ensuring reliable performance across clinical applications . The product catalog spans cardiac biomarkers (troponin I, D-Dimer, BNP), infectious disease markers (MxA, CRP, PCT), fertility hormones (AMH, LH, FSH), and metabolic disease targets (HbA1c, 25-OH Vitamin D) . This breadth positions Sekbio as a comprehensive source for IVD manufacturers seeking validated, clinically relevant raw materials.
Engineering Excellence: CHO and HEK293 Expression Platforms
What truly distinguishes Sekbio is its proprietary recombinant protein expression infrastructure. The company has developed high-performance CHO and HEK293 cell line platforms that drive both speed and yield in antibody production . With the CHO system achieving expression titers up to 2.4 g/L and a rapid 7-day delivery option for urgent projects, Sekbio enables diagnostic developers to accelerate their timelines significantly . The platform has successfully delivered over 800 expression projects, with more than 1,800 proteins expressed in the HEK293 system alone .
This engineering capability extends to stable cell line development—a critical service for manufacturers seeking long-term supply security. Sekbio reports a 94%+ success rate in establishing stable CHO and HEK293 cell lines, with an end-to-end timeline of 2–3 months at a fraction of traditional costs . By offering transient expression screening for under $1,000, Sekbio lowers the barrier to entry for startups and research institutions aiming to commercialize novel biomarkers .
Innovation in Small Molecule Development: AI-Assisted Hapten Synthesis
Beyond large-molecule antigens, Sekbio has invested heavily in addressing one of the industry's most persistent technical bottlenecks: hapten-based immunoassay development. Small molecule targets such as steroid hormones, vitamins, and drug metabolites present unique challenges due to their size and structural complexity. Sekbio's AI-assisted chemical synthesis platform narrows the candidate pool of derivatization sites and linker chemistries before wet-lab synthesis begins, dramatically shortening the iteration cycle between structural design and assay-level validation . This approach, presented by Founder and CEO Jack Sun at Diagmand 2026, exemplifies Sekbio's commitment to solving difficult chemistry problems through computational and experimental integration .
CDMO Capabilities: From Target to Manufactured Product
Sekbio has developed a comprehensive CDMO (Contract Development and Manufacturing Organization) one-stop model that guides clients from validated target to manufacturable IVD raw material . This integrated service encompasses product optimization, recombinant antibody and raw material engineering, production line setup and scale-up, and after-sales technical support . By owning the entire pipeline under one roof, Sekbio eliminates the fragmented handoffs that typically slow timelines and compromise quality. The CDMO model is particularly valuable for research institutions and startups that hold promising biomarker patents but lack industrialization capability—a gap Sekbio is uniquely positioned to bridge .
Global Reach and Industry Engagement
With a client base spanning more than 200 IVD brands across 30+ countries, Sekbio has demonstrated its ability to serve diverse markets from European diagnostic leaders to emerging-market rapid test manufacturers . The company's active participation in global trade fairs, including Medica 2025 in Düsseldorf, highlights its commitment to face-to-face engagement with IVD engineers, procurement managers, and startup founders . At Medica 2025, the discussion topics ranged from antibody stable cell line development to rapid test kit validation, with visitors particularly interested in Sekbio's cost-effective approach to production cell line establishment .
Conclusion
Sekbio represents a new generation of IVD raw material suppliers—one that combines scientific rigor, manufacturing scale, and technological innovation to serve the global diagnostic community. From its ISO 13485-certified quality management system to its AI-enhanced development platforms, Sekbio has built an infrastructure designed for the future of diagnostics . Whether through its comprehensive product portfolio, efficient CDMO services, or commitment to solving complex hapten development challenges, Sekbio continues to establish itself as a trusted partner for diagnostic manufacturers worldwide. As the IVD industry evolves toward greater sensitivity, specificity, and accessibility, Sekbio stands ready to supply the essential raw materials that make advanced diagnostic testing possible.
Top comments (0)